Ubs Group Ag Replimune Group, Inc. Transaction History

Ubs Group Ag

$527 Billion
Q4 2024

A detailed history of Ubs Group Ag transactions in Replimune Group, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 95,447 shares of REPL stock, worth $1.35 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

95,447

Previous 91,017 4.87%

Holding current value

$1.35 Million

Previous $997,000 15.85%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$10.54 - $14.93 $46,692 - $66,139	4,430 Added 4.87%	95,447 $1.16 Million
Q3 2024 Nov 14, 2024	BUY	$8.09 - $11.23 $548,421 - $761,281	67,790 Added 291.86%	91,017 $997,000
Q2 2024 Aug 13, 2024	SELL	$5.01 - $9.46 $1.73 Million - $3.26 Million	-344,759 Reduced 93.69%	23,227 $209,000
Q1 2024 May 13, 2024	BUY	$6.87 - $9.31 $1.01 Million - $1.37 Million	147,559 Added 66.94%	367,986 $3.01 Million
Q4 2023 Feb 09, 2024	BUY	$6.75 - $16.18 $1.08 Million - $2.6 Million	160,484 Added 267.73%	220,427 $1.86 Million
Q3 2023 Nov 09, 2023	BUY	$15.96 - $22.18 $514,055 - $714,395	32,209 Added 116.14%	59,943 $1.03 Million
Q2 2023 Aug 11, 2023	SELL	$15.65 - $24.1 $890,172 - $1.37 Million	-56,880 Reduced 67.22%	27,734 $643,000
Q1 2023 May 12, 2023	BUY	$17.48 - $29.09 $439,674 - $731,700	25,153 Added 42.3%	84,614 $1.49 Million
Q4 2022 Feb 08, 2023	BUY	$17.09 - $27.91 $904,197 - $1.48 Million	52,908 Added 807.39%	59,461 $1.62 Million
Q3 2022 Nov 10, 2022	SELL	$15.6 - $21.15 $336,086 - $455,655	-21,544 Reduced 76.68%	6,553 $114,000
Q2 2022 Aug 10, 2022	SELL	$13.32 - $19.98 $883,595 - $1.33 Million	-66,336 Reduced 70.25%	28,097 $491,000
Q1 2022 May 16, 2022	BUY	$15.24 - $29.75 $480,166 - $937,333	31,507 Added 50.07%	94,433 $1.6 Million
Q4 2021 Feb 14, 2022	BUY	$25.43 - $34.25 $898,696 - $1.21 Million	35,340 Added 128.11%	62,926 $1.71 Million
Q3 2021 Nov 15, 2021	BUY	$28.98 - $39.54 $565,486 - $771,544	19,513 Added 241.71%	27,586 $818,000
Q2 2021 Aug 13, 2021	SELL	$28.5 - $39.37 $1.04 Million - $1.44 Million	-36,552 Reduced 81.91%	8,073 $310,000
Q1 2021 May 12, 2021	BUY	$30.22 - $45.57 $1.27 Million - $1.91 Million	41,970 Added 1580.79%	44,625 $1.36 Million
Q4 2020 Feb 11, 2021	BUY	$23.5 - $52.65 $62,392 - $139,785	2,655 New	2,655 $101,000
Q3 2020 Nov 12, 2020	SELL	$18.85 - $27.0 $124,824 - $178,794	-6,622 Closed	0 $0
Q2 2020 Jul 31, 2020	SELL	$9.76 - $25.95 $329,068 - $874,930	-33,716 Reduced 83.58%	6,622 $165,000
Q1 2020 May 01, 2020	BUY	$8.9 - $19.08 $358,269 - $768,065	40,255 Added 48500.0%	40,338 $402,000
Q4 2019 Feb 14, 2020	SELL	$11.61 - $17.21 $49,040 - $72,695	-4,224 Reduced 98.07%	83 $1,000
Q3 2019 Nov 14, 2019	BUY	$10.01 - $16.87 $43,113 - $72,659	4,307 New	4,307 $60,000
Q2 2019 Aug 14, 2019	SELL	$12.51 - $17.28 $13,235 - $18,282	-1,058 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$10.26 - $16.24 $595 - $941	58 Added 5.8%	1,058 $16,000
Q4 2018 Feb 14, 2019	SELL	$9.97 - $15.57 $7,756 - $12,113	-778 Reduced 43.76%	1,000 $10,000
Q3 2018 Nov 14, 2018	BUY	$14.99 - $22.14 $26,652 - $39,364	1,778 New	1,778 $29,000

Others Institutions Holding REPL

# of Institutions

158

Shares Held

76.1M

Call Options Held

40.6K

Put Options Held

53K

View Full List

About Replimune Group, Inc.

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $695M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

More about REPL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account